Purpose The purpose of this paper was to undertake a systematic review of literature on methicillin-resistant
Introduction
Staphylococcus aureus has been long associated with a wide spectrum of infectious diseases ranging from skin infections including impetigo, furuncles, folliculitis, carbuncles, abscesses, wound infections to more serious infections such as pneumonia, meningitis, osteomyelitis, endocarditis, toxic shock syndrome, staphylococcal bacteremia, and sepsis. This Gram-positive micro-organism has been frequently reported to have acquired resistance to antimicrobials [1] . Methicillin-resistant Staphylococcus aureus (MRSA) infections were first described after the introduction of methicillin in 1959 [2] . S. aureus and MRSA have been reported to colonize as commensals in humans without causing infection. Over the past few years, MRSA has emerged as one of the most dreaded nosocomial pathogens, responsible for multiple institutional outbreaks [1] . The oral and nasal cavities are regions that commonly harbor MRSA [3] . Recent reports of MRSA strains circulating at the community level are on the rise [4, 5] . It has been emphasised in a retrospective study by Minoru Miyake et al. [6] that elimination of MRSA is of critical importance in oral and maxillofacial surgical practice, as control is very difficult once infection of an oral tumor or oral wound with MRSA is established. Recently, Infectious Diseases Society of America (IDSA) has released its first guidelines, for the treatment of increasingly common MRSA infections [7] . The presented study reviews the available literature in oral and maxillofacial online databases and discusses the IDSA guidelines and its application in maxillofacial clinical practice.
Materials and Methods
A systematic search of the literature was carried out to identify eligible articles. The investigators searched the literature using the terms ''methicillin-resistant Staphylococcus aureus'' and ''MRSA'' in the online databases of 
Results
Out of 18 articles found with the search terms ''methicillinresistant Staphylococcus aureus'' and ''MRSA'' in the online databases 12 articles met the inclusion criteria for this study. The relevant data was extracted and tabulated (Table 1) . Conclusions were drawn and discussed based on the reviewed maxillofacial literature and the Guidelines by the IDSA.
Discussion
MRSA is a common nosocomial infection that worsens prognosis, increase the length of the hospital stay and is a great financial burden on the health care systems worldwide. It was the need of the day to have clear guidelines on management of infections complicated by the presence of MRSA. The 13 member MRSA guidelines panel was convened by the IDSA Standards and Practice Guidelines Committee in 2007 to develop evidence-based guidelines for managing patients with MRSA infections, the outcome of which forms a framework for clinicians to handle MRSA infections in a more systematic manner [7] . The guidelines are based on the review and analysis of data published from 1961 to 2010 in PUBMED, abstracts, national meetings, randomized clinical trials, observational studies, case series and the opinion of the expert panel.
Although the published reports of MRSA infection in the searched data bases for this study remained low, a clear understanding on managing such infections when encountered is essential (Fig. 1) . In maxillofacial surgical practice, the most common group of patients to have MRSA infections were cancer patients treated with primary resections and requiring reconstruction with free flaps Table 2 Conditions requiring antibiotic therapy for abscesses [7] Antibiotic therapy is recommended for abscesses associated with the following conditions Table 3 Antibiotics for patients requiring hospitalization for skin and soft tissue infections [7] Drug Dosage [8, 9] . A few cases of osteomyelitis of jaws complicated with MRSA are reported [1, 10, 11] . Bruno et al. [5] have reported a case of community acquired MRSA lip infection that progressed to necrotizing pneumonia and patient expired inspite of administration of appropriate antimicrobials and intensive care. Reports of MRSA infections following dento-alveolar procedures like dental implants and sinus lift is a warning signal warranting strict asepsis in all maxillofacial and dental setups [12] . According to the recommendations of Liu et al. [7] in the IDSA guidelines on management of MRSA infections, simple abscesses or boils would require incision and drainage alone, and antibiotic therapy is not needed. Antibiotic therapy is recommended for abscesses associated with the conditions summarized in Table 2 . Among skin and soft tissue infections with current evidence of knowledge, purulent cellulitis should be treated empirically for MRSA and nonpurulent cellulitis should be treated empirically for b-hemolytic streptococci. Culture and sensitivity tests of appropriate biological samples should be sought. Based on the recommendations, oral antibiotics for community acquired MRSA are clindamycin, trimethoprim-sulfamethoxazole, a tetracycline (doxycycline/ minocycline), or linezolid for a period of 5-10 days individualized on the basis of the patient's clinical response. Patients requiring hospitalization for skin and soft tissue infections should receive a thorough surgical debridement, broad-spectrum antibiotics, and empiric MRSA treatment that includes intravenous vancomycin, oral or intravenous linezolid, daptomycin, telavancin, or clindamycin for a period of 7-14 days (Table 3) .
Teeth bearing maxillofacial skeleton is commonly affected by osteomyelitis, which is one of the feared condition by most maxillofacial surgeons to treat [13] . Septic arthritis of the temporomandibular joint is a rare condition with high morbidity [14] . With the advent of various TMJ prosthesis, a vast number of patients are requiring total joint reconstruction are benefited. Although TMJ total joint prostheses can become infected, as any other prosthetic device in the human system [15] . According to the recommendations [7] , for the management of MRSA bone and joint infections (osteomyelitis, septic arthritis and infections involving joint prosthesis) surgical debridement and drainage should be given emphasis and remain the mainstay of the treatment. Antibiotics for parenteral administration include vancomycin and daptomycin, trimethoprimsulfamethoxazole in combination with rifampin, linezolid, clindamycin and refampin in combination to any of the previously mentioned antimicrobials. ESR and CRP levels are useful investigations to guide the clinicians to assess response to the therapy. Recommendations for choice of the antimicrobial, dosage and the duration for MRSA bone and joint infections is summarised in Table 4 .
It is not infrequent in maxillofacial surgical practice to encounter patients who are at a risk of developing bacteremia [16] and infective endocarditis [17] . Although the treatment and management of patients for MRSA bacteremia and infective endocarditis is beyond the scope of maxillofacial surgical practice, an insight in the drugs used for their management remains beneficial as many such patients may have associated MRSA soft or hard tissue facial infections. Vancomycin or daptomycin remains the recommended antimicrobials for uncomplicated bacteremia for at least 2 weeks where as complicated bacteremias need treatment for 4-6, and 6 weeks treatment for MRSA infective endocarditis [7] . Current evidence clearly demonstrates that vancomycin remains the drug of choice for MRSA infections. According to IDSA guidelines [7] , in adults the dose of IV vancomycin is 15-20 mg/kg/dose every 8-12 h and should not exceed 2 g per dose. In children administration of 15 mg/ kg/dose every 6 h is recommended. Determining ''trough vancomycin concentration'' is the most accurate and practical method to guide vancomycin dosing. Trough monitoring is recommended to achieve target concentrations of 15-20 lg/mL in patients with serious MRSA infections. In cases with skin and soft tissue infections, the vancomycin dose of 1 g every 12 h should suffice and trough levels monitoring is not necessary.
Treatment of MRSA infections is challenging. Prevention remains better than cure as MRSA infections once established require herculean efforts to attain resolution. The importance of strict adherence to sterilisation and asepsis protocols, good wound care with clean dry bandages, personal and environmental hygiene, surveillance cultures, decolonization and scientifically justified use of antimicrobial therapy should never be under-estimated.
Conclusions
IDSA guidelines have laid a framework for the management of patients with MRSA infections. Although published reports lack in number, maxillofacial MRSA infections are on the rise. Vancomycin remains the drug of choice for MRSA infections with adults dosage of IV vancomycin of 15-20 mg/kg/dose every 8-12 h which should not exceed 2 g/dose. For paediatric group dosage of 15 mg/kg/dose every 6 h is recommended.
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